These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22884754)

  • 1. Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
    Roiz-Santiáñez R; Tordesillas-Gutiérrez D; Ortíz-García de la Foz V; Ayesa-Arriola R; Gutiérrez A; Tabarés-Seisdedos R; Vázquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2012 Oct; 141(1):22-8. PubMed ID: 22884754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
    Crespo-Facorro B; Roiz-Santiáñez R; Pérez-Iglesias R; Pelayo-Terán JM; Rodríguez-Sánchez JM; Tordesillas-Gutiérrez D; Ramírez M; Martínez O; Gutiérrez A; de Lucas EM; Vázquez-Barquero JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1936-43. PubMed ID: 18930104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
    J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic drug effects on brain morphology in first-episode psychosis.
    Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
    Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
    Sergi MJ; Green MF; Widmark C; Reist C; Erhart S; Braff DL; Kee KS; Marder SR; Mintz J
    Am J Psychiatry; 2007 Oct; 164(10):1585-92. PubMed ID: 17898351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
    Rémillard S; Pourcher E; Cohen H
    Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral cortical gray expansion associated with two second-generation antipsychotics.
    Garver DL; Holcomb JA; Christensen JD
    Biol Psychiatry; 2005 Jul; 58(1):62-6. PubMed ID: 15992524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
    Crespo-Facorro B; Pérez-Iglesias R; Mata I; Caseiro O; Martínez-Garcia O; Pardo G; Ramirez-Bonilla M; Pelayo-Terán JM; Vázquez-Barquero JL
    J Psychiatr Res; 2011 Jun; 45(6):763-9. PubMed ID: 21106207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No progression of the alterations in the cortical thickness of individuals with schizophrenia-spectrum disorder: a three-year longitudinal magnetic resonance imaging study of first-episode patients.
    Roiz-Santiáñez R; Ortiz-García de la Foz V; Ayesa-Arriola R; Tordesillas-Gutiérrez D; Jorge R; Varela-Gómez N; Suárez-Pinilla P; Córdova-Palomera A; Navasa-Melado JM; Crespo-Facorro B
    Psychol Med; 2015 Oct; 45(13):2861-71. PubMed ID: 26004991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
    Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
    Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
    Keefe RS; Young CA; Rock SL; Purdon SE; Gold JM; Breier A;
    Schizophr Res; 2006 Jan; 81(1):1-15. PubMed ID: 16202565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
    Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
    Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.
    Goghari VM; Smith GN; Honer WG; Kopala LC; Thornton AE; Su W; Macewan GW; Lang DJ
    Schizophr Res; 2013 Sep; 149(1-3):149-55. PubMed ID: 23830856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
    Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ramirez-Bonilla M; Martínez-Garcia O; Pardo-Garcia G; Caseiro O; Pelayo-Terán JM; Vázquez-Barquero JL
    J Psychopharmacol; 2011 Jun; 25(6):744-54. PubMed ID: 21292922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
    Lataster J; van Os J; de Haan L; Thewissen V; Bak M; Lataster T; Lardinois M; Delespaul PA; Myin-Germeys I
    J Clin Psychiatry; 2011 Oct; 72(10):1397-404. PubMed ID: 21208588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
    Ayesa-Arriola R; Rodríguez-Sánchez JM; Pérez-Iglesias R; Roiz-Santiáñez R; Martínez-García O; Sánchez-Moreno J; Tabarés-Seisdedos R; Vázquez-Barquero JL; Crespo-Facorro B
    Psychopharmacology (Berl); 2013 Jun; 227(4):615-25. PubMed ID: 23455591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.